Il nostro standard di qualità: qualità lotto dopo lotto

Avextra è sinonimo di farmaci a base di cannabis di alta qualità. La nostra chiave del successo: la coltivazione in Portogallo e la combinazione di tradizione e alta tecnologia. Per saperne di più, guardate il video con il nostro CMO David Reckeweg-Lecompte.

Podcasts

Neil Smith è ospite da Planted con Sara Payan.

Sara Payan parla con Neil Smith, COO di Avextra, della situazione della cannabis in Europa e dei nuovi sviluppi della ricerca. Qui trovi l’intervista in inglese.

Comunicati stampa

Qui trovate gli ultimi comunicati stampa di Avextra.

Avextra Cannabis extract can potentially reduce symptom burden for late palliative patients

Avextra Cannabis extract can potentially reduce symptom burden for late palliative patients

Bensheim, Germany, 13th June 2025 — New Study Demonstrates Significant Symptom Relief for Late-Stage Palliative Patients Treated with Cannabis-based Medicines…

Veteran Banker Joins Avextra’s Supervisory Board

Veteran Banker Joins Avextra’s Supervisory Board

Bensheim, Germany, April 3, 2025 – Dr. Stefan Jentzsch, Partner at the global investment firm Perella Weinberg Partners has been appointed to Avextra’s Supervisory Board,…

Avextra Showcases Study Findings on World Sleep Day 2025

Avextra Showcases Study Findings on World Sleep Day 2025

Bensheim, Germany – 14 March 2025 – In anticipation of World Sleep Day, Avextra has revealed findings from its IMPACT study at the German Pain and Palliative Care Days, organised by the German Pain Association…

Avextra Unveils Promising Study Results at Major Pain Congress

Avextra Unveils Promising Study Results at Major Pain Congress

Bensheim, Germany – 13 March 2025 – At its annual congress in Frankfurt, Germany, this week, researchers from the DGS will be presenting the results of the retrospective register study OCEAN-R, supported by Avextra…

Avextra expanding its product portfolio of cannabis-based medicines

Avextra expanding its product portfolio of cannabis-based medicines

Bensheim, Germany, 6 March 2025 — Avextra is broadening its product portfolio with a 25/25 cannabis extract and is presenting initial study results during the German Pain and Palliative Care Days…

Avextra Portugal stellt sein State-of-the-Art Pflanzengenetik-Programm zur Entwicklung eigener THC- und CBD-Kultivare vor

Avextra Portugal stellt sein State-of-the-Art Pflanzengenetik-Programm zur Entwicklung eigener THC- und CBD-Kultivare vor

Lissabon, Portugal, 20. November 2024 — Avextra Portugal stellt sein innovatives internes Pflanzen-Genetikprogramm vor…

Deutsches Start-up Avextra will „Cannabis-Blockbuster“ entwickeln

Deutsches Start-up Avextra will „Cannabis-Blockbuster“ entwickeln

Das Handelsblatt hat das hessische Cannabis-Biotech-Unternehmen Avextra porträtiert und gibt Einblicke in die Arzneimittelentwicklung Made in Germany.

Avextra Cannabis extract can potentially reduce symptom burden for late palliative patients

Avextra Cannabis extract can potentially reduce symptom burden for late palliative patients

Bensheim, Germany, 13th June 2025 — New Study Demonstrates Significant Symptom Relief for Late-Stage Palliative Patients Treated with Cannabis-based Medicines…

Veteran Banker Joins Avextra’s Supervisory Board

Veteran Banker Joins Avextra’s Supervisory Board

Bensheim, Germany, April 3, 2025 – Dr. Stefan Jentzsch, Partner at the global investment firm Perella Weinberg Partners has been appointed to Avextra’s Supervisory Board,…

Avextra Showcases Study Findings on World Sleep Day 2025

Avextra Showcases Study Findings on World Sleep Day 2025

Bensheim, Germany – 14 March 2025 – In anticipation of World Sleep Day, Avextra has revealed findings from its IMPACT study at the German Pain and Palliative Care Days, organised by the German Pain Association…

Avextra Unveils Promising Study Results at Major Pain Congress

Avextra Unveils Promising Study Results at Major Pain Congress

Bensheim, Germany – 13 March 2025 – At its annual congress in Frankfurt, Germany, this week, researchers from the DGS will be presenting the results of the retrospective register study OCEAN-R, supported by Avextra…

Avextra expanding its product portfolio of cannabis-based medicines

Avextra expanding its product portfolio of cannabis-based medicines

Bensheim, Germany, 6 March 2025 — Avextra is broadening its product portfolio with a 25/25 cannabis extract and is presenting initial study results during the German Pain and Palliative Care Days…

Avextra Portugal Unveils Advanced Breeding Program to Develop Proprietary THC and CBD Cultivars, Establishing a Key IP Pillar

Avextra Portugal Unveils Advanced Breeding Program to Develop Proprietary THC and CBD Cultivars, Establishing a Key IP Pillar

Lisbon, Portugal, November 20, 2024 — Avextra Portugal is excited to announce that its innovative in-house breeding program is now operational…

German start-up Avextra wants to develop “cannabis blockbusters”.

German start-up Avextra wants to develop “cannabis blockbusters”.

The Leading German Business Publication Handelsblatt did a profile on the German cannabis biotech company Avextra providing insights into botanical drug development Made in Germany.

UFFICIO STaMPa

Lisa Schwede

Tel.: +49 30 408174037

E-Mail: press@avextra.com

IT